Literature DB >> 11350489

Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis.

H Wang1, T Chuhjo, H Yamazaki, S Shiobara, M Teramura, H Mizoguchi, S Nakao.   

Abstract

To clarify the pathologic significance of granulocytes exhibiting the paroxysmal nocturnal haemoglobinuria (PNH) phenotype in patients with aplastic anaemia (AA), we examined peripheral blood from 100 patients with AA for the presence of granulocytes deficient in glycosylphosphatidylinositol (GPI)-anchored proteins using a sensitive flow cytometric assay. A significant increase in the frequency of CD55-CD59-CD11b+ granulocytes (>0.003%) compared to normal individuals was observed in 31 of 35 (88.6%) patients with untreated AA at diagnosis. The proportions of patients showing increased PNH granulocytes in treated AA patients with a short (<5 yr) and long (>5 yr) disease duration were 68.6% (11/16) and 20.4% (10/49), respectively. When 19 patients showing increased frequency of PNH granulocytes before therapy were studied 6-12 months after antithymocyte globulin plus cyclosporin A therapy, the frequency decreased to 0.01-90% of pretreatment values in 15 recovering patients. These findings suggest that a relative increase in the number of PNH granulocytes is a common feature of AA at diagnosis, and that it may represent the presence of immunologic pressure to normal haematopoietic stem cells as a cause of AA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11350489     DOI: 10.1034/j.1600-0609.2001.00376.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  16 in total

1.  Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia.

Authors:  Atsushi Narita; Hideki Muramatsu; Yuko Sekiya; Yusuke Okuno; Hirotoshi Sakaguchi; Nobuhiro Nishio; Nao Yoshida; Xinan Wang; Yinyan Xu; Nozomu Kawashima; Sayoko Doisaki; Asahito Hama; Yoshiyuki Takahashi; Kazuko Kudo; Hiroshi Moritake; Masao Kobayashi; Ryoji Kobayashi; Etsuro Ito; Hiromasa Yabe; Shouichi Ohga; Akira Ohara; Seiji Kojima
Journal:  Haematologica       Date:  2015-08-27       Impact factor: 9.941

Review 2.  New insights into molecular pathogenesis of bone marrow failure in paroxysmal nocturnal hemoglobinuria.

Authors:  Tatsuya Kawaguchi; Hideki Nakakuma
Journal:  Int J Hematol       Date:  2007-07       Impact factor: 2.490

Review 3.  Immune pathophysiology of aplastic anemia.

Authors:  Shinji Nakao; Xingmin Feng; Chiharu Sugimori
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

4.  The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells.

Authors:  Jeffrey J Pu; Rong Hu; Galina L Mukhina; Hetty E Carraway; Michael A McDevitt; Robert A Brodsky
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

Review 5.  Molecular genetics of paroxysmal nocturnal hemoglobinuria.

Authors:  Norimitsu Inoue; Yoshiko Murakami; Taroh Kinoshita
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

6.  Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles.

Authors:  Weihua Zeng; Akira Miyazato; Guibin Chen; Sachiko Kajigaya; Neal S Young; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2005-08-30       Impact factor: 22.113

Review 7.  Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia.

Authors:  Atsushi Narita; Seiji Kojima
Journal:  Int J Hematol       Date:  2016-04-18       Impact factor: 2.490

Review 8.  Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood Rev       Date:  2007-12-03       Impact factor: 8.250

9.  How I treat paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

10.  Increased plasma thrombopoietin levels in patients with myelodysplastic syndrome: a reliable marker for a benign subset of bone marrow failure.

Authors:  Yu Seiki; Yumi Sasaki; Kohei Hosokawa; Chizuru Saito; Naomi Sugimori; Hirohito Yamazaki; Akiyoshi Takami; Shinji Nakao
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.